Lilly Readies Web Portal for PD2 Initiative; University of Cincinnati Joins List of Participants

Under the Phenotypic Drug Discovery program, researchers from academia or biotech submit candidate compounds in specific therapeutic areas for Lilly to evaluate and profile. Participating organizations retain full IP rights to the compounds, but Lilly receives first rights to negotiate a broader collaboration or licensing agreement.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories